seed
Stage
1
Investors
About
WaveBreak develops small-molecule drugs targeting transient protein intermediates involved in neurodegenerative diseases, aiming to treat conditions such as Parkinson’s disease, Alzheimer's disease, Lewy body dementia, and ALS.
Explore WaveBreak's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.